Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis

•SABR in oligometastatic breast cancer is safe and correlated with high rates of local control.•In the meta-regression analysis prospective design (p = 0.001) and bone-only metastases (p = 0.01) were significantly associated with better OS.•Hormone receptor status was associated with improved local control (p = 0.01) on meta-regression analysis.•Longer follow-up of existing data and ongoing prospective trials will help further define the role of this management strategy. Stereotactic ablative radiotherapy (SABR) has been reported to be an effective treatment for oligometastatic disease from different primary cancer sites. Here we assess the effectiveness and safety of SABR for oligometastatic breast cancer patients by performing a meta-analysis. Following PRISMA and MOOSE guidelines, a systematic review and meta-analysis was performed. Eligible studies were identified on Medline, Embase, Cochrane Library, and annual meetings proceedings from 1990 to June 2021. A meta-regression analysis was performed to assess if there was a correlation between moderator variables and outcomes, and a p-value